An Improved PID Switching Control Strategy for Type 1 Diabetes



Similar documents
Reference. United States. 1. Introduction

Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control

Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric

A Fuzzy Controller for Blood Glucose-Insulin System

Abstract SYMPOSIUM. Journal of Diabetes Science and Technology

Insulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake

Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices

Novel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented Pump and Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes Mellitus

ARTICLE IN PRESS Biomedical Signal Processing and Control xxx (2012) xxx xxx

A run-to-run framework for prandial insulin dosing: handling real-life uncertainty

The Quantified Self on Steroids: Innovation in Devices, Pumps and Monitors

Glucose-Insulin System based on Minimal Model: a Realistic Approach

The Exploitation of Using Sliding Table Controller in Blood Glucose-Insulin System for Diabetes

CONTROL SYSTEM FOR INSULIN PUMPS IN THE MELLITUS DIABETES TREATMENTS

Self-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime.

Universita degli Studi di Padova Facolta di Ingegneria

Calculating Insulin Dose

Robust Control of Type 1 Diabetes using µ-synthesis

B. Braun Space GlucoseControl (SGC)

A Model of Glucose Evolution in Type 1 Diabetes Patients

Closed loop insulin delivery systems

INSULIN PRODUCTS. Jack DeRuiter

Dietfree-Good News for Diabetics

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US

Type 1 Diabetes - How the HHM System Evaluates Its Performance

THE availability of a simulation model of the glucose-insulin

CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies

Research Article Continuous Drug Infusion for Diabetes Therapy: A Closed-Loop Control System Design

A Model-Based Approach to Synthesizing Insulin Infusion Pump Usage Parameters for Diabetic Patients

Supplementary appendix

Algorithms for Glycemic Management of Type 2 Diabetes

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

WHY THE IMPLANTABLE INSULIN PUMP WORKS SO WELL

Automated insulin delivery for type 1 diabetes Garry M. Steil a and Mohammed F. Saad b

Insulin therapy in various type 1 diabetes patients workshop

Minimal Models for Glucose and Insulin Kinetics

Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus

Intensive Insulin Therapy in Diabetes Management

CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW

Dr. Yeffry Handoko Putra, S.T., M.T

Diabetes Care 36: , 2013

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:

Using Wireless Measurements in Control Applications

Artificial Pancreas Using a Personalized Rule-Based Controller Achieves Overnight Normoglycemia in Patients with Type 1 Diabetes

Numerous studies have demonstrated that utilization

Insulin pump therapy aiming for better blood glucose control in people with diabetes

Abdulaziz Al-Subaie. Anfal Al-Shalwi

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

Automatic Blood Glucose Control in Diabetes

Anomaly Detection in the Artificial Pancreas

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

Introduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.

SYSTEMS AND INFORMATION ENGINEERING

Intensifying Insulin Therapy

Continuous Subcutaneous Insulin Infusion (CSII)

Type 1 Diabetes - Managing a Critical Ratio

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing

Present and Future of Insulin Therapy: Research Rationale for New Insulins

[Frida Svendsen and Jennifer Southern] University of Oxford. October 2014

WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?

Insulin and Diabetes

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

NCT sanofi-aventis HOE901_3507. insulin glargine

Diabetes mellitus. Lecture Outline

CONTINUOUS PERFORMANCE MONITORING OF A CLOSED-LOOP INSULIN DELIVERY SYSTEM USING BAYESIAN SURPRISE

A Virtual Type 1 Diabetes Patient

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Basal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction)

AN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS

The What, Why, Who & How of Insulin Pumps. Bridget Lydon May 2014

INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL

Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE

Insulin Pump Management and Continuous Glucose Monitoring Systems (CGMS)

Diabetes Medical Management Plan (DMMP)

Implementation of Fuzzy and PID Controller to Water Level System using LabView

Starting patients on the V-Go Disposable Insulin Delivery Device

Lambda Tuning the Universal Method for PID Controllers in Process Control

Artificial Neural Network Algorithm for On-Line Glucose Prediction from Continuous Glucose Monitoring

Is what you know about INSULIN PUMP THERAPY. This educational resource is provided by Medtronic MiniMed, Inc.

CGC s Hybrid System Loop Control

UNIVERSITY OF SOUTHERN QUEENSLAND

Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems

4/15/2013. Maribeth Inturrisi RN MS CNS CDE Perinatal Diabetes Educator

Best Practices for Controller Tuning

MANAGING DIET ON AN INSULIN PUMP.

FAST METHODS FOR SLOW LOOPS: TUNE YOUR TEMPERATURE CONTROLS IN 15 MINUTES

BLOOD GLUCOSE MONITORING MEDICATION

Diabetes Medications: Insulin Therapy

Model Predictive Control Algorithms for Pen and Pump Insulin Administration

Are you ready to pump?

Medical Policy Insulin Pumps

Insulin pump therapy: a practical guide to optimising glycaemic control

Pump Therapy Indications:

4/7/2015 CONFLICT OF INTEREST DISCLOSURE OBJECTIVES. Conflicts of Interest None Heather Rush. Heather M. Rush, APRN, CDE Louisville, KY

Controller Design in Frequency Domain

Deterministic and Stochastic Modeling of Insulin Sensitivity

Microcontroller-based experiments for a control systems course in electrical engineering technology

On Quantitative Software Quality Assurance Methodologies for Cardiac Pacemakers

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes.

ALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan

Transcription:

An Improved PID Switching Control Strategy for Type 1 Diabetes Gianni Marchetti, Massimiliano Barolo, Lois Jovanovic, Howard Zisser, and Dale E. Seborg, Member, IEEE Department of Chemical Engineering Principles and Practice, Università di Padova (Italy) Sansum Diabetes Research Institute, 2219 Bath St., Santa Barbara, CA 93105 Department of Chemical Engineering, University of California Santa Barbara, Santa Barbara, CA 93106-50 Abstract In order for an artificial pancreas to become a reality for ambulatory use, a practical closed-loop control strategy must be developed and critically evaluated. In this paper, an improved PID control strategy for blood glucose control is proposed and evaluated in silico using a physiologic model of Howorka et al. [1]. The key features of the proposed control strategy are: (i) a switching strategy for initiating PID control after a meal and insulin bolus; (ii) a novel time-varying setpoint trajectory, (iii) noise and derivative filters to reduce sensitivity to sensor noise, and (iv) a systematic controller tuning strategy. Simulation results demonstrate that proposed control strategy compares favorably to alternatives for realistic conditions that include meal challenges, incorrect carbohydrate meal estimates, changes in insulin sensitivity, and measurement noise. I. INTRODUCTION People with type 1 diabetes must rely on exogenous insulin for survival. The current treatment method requires either multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) delivered via a pump. Both treatment modes necessitate blood glucose (fingerstick) measurements throughout the day in order to determine insulin boluses for mealtimes; also, one to three injections or programming continuous infusion of short-acting insulin via CSII are required to maintain normoglycemia between meals. For people with type 1 diabetes, tight glucose control has been difficult to achieve due to the infrequent measurements, patient variability, and changes in insulin sensitivity due to exercise, stress, illness, etc. Consequently, there has been considerable interest in developing an artificial pancreas, a portable (or implantable) automated insulin delivery system that consists of three components: a glucose sensor which provides frequent measurements (e.g., every five minutes), an insulin infusion pump, and a control algorithm which calculates the appropriate insulin dosage for the current conditions. During the past 30 years, a variety of glucose control strategies based on continuous glucose sensing has been reported. Since this literature has been reviewed in recent survey articles [2] [5], we will not present a detailed review here. In summary, the control strategies include variations This research was supported by the National Institutes of Health, grant R21 DK069833 Correspondence to: University of California Santa Barbara, Department of Chemical Engineering, Santa Barbara, CA 93106-50. seborg@engineering.ucsb.edu of the proportional-integral-derivative (PID) control strategy that is widely used in industrial control applications [6]. A PID control strategy is attractive for glucose control because it mimics the first and second phase responses that the pancreas beta cells use to control glucose. This paper is concerned with developing an improved glucose controller that is based on a novel PID controller, bolus injections for meals, and a strategy for switching between them. Controller performance is evaluated for realistic conditions such as poor (meal) carbohydrate estimates, changes in insulin sensitivity, and measurement noise. II. PHYSIOLOGICAL MODEL Many physiological models have been proposed that describe glucose and/or insulin dynamics [1], [7] [10]. In this paper, the simulation studies are based on the model developed by Hovorka et al. [1] and the modifications reported to Wilinska et al. [10]. This model will be referred to as the Hovorka model. It represents the relationship between input variables, subcutaneous insulin infusion rates (basal and bolus), and the output variable, intravenous glucose concentration. This model also includes a submodel for meal ingestion. The Hovorka model is a nonlinear compartmental model with three subsystems for glucose, insulin, and insulin action. The values of the model parameters were determined from experimental data for both normal and diabetic subjects. In order to simulate the measurement noise of the glucose sensor, a normally distributed random error, ɛ, with mean zero and variance equal to 0.00111 was introduced, G m = G(1 + ɛ), where G m (mg/dl) is the measured value. III. PID CONTROLLER DESIGN A variety of PID control strategies have been developed for diabetes control and described in survey papers and review articles [2] [5]. Most of the related evaluations have been based on simulation studies but experimental applications to dogs or humans have also been reported. The PID controller calculates the insulin infusion rate that is released by the pump into subcutaneous tissues. The velocity form of the PID controller was used [6]. In order to reduce the effect of noise, the measured glucose concentration, G m, was filtered using a standard first-order filter [6]. Furthermore, a derivative filter was used in the controller itself.

In an initial study, the PID controller was tuned for meal challenges. However, it was not possible to avoid postprandial hypoglycemia unless the reset time was set to very large values (e.g., τ I = 167 h), which essentially eliminated the effect of integral control action. On the other hand, it is desirable to include integral action to deal with patient variability such as changes in insulin sensitivity. One solution to this problem is to limit the integral term by introducing upper and lower limits. With this constraint, the effect of the integral action for meal challenge is negligible compared to the effects of proportional and derivative action, but integral action will eliminate steady-state error (offset) in G m after insulin sensitivities changes. Based on these considerations, a novel controller tuning procedure was employed. First, K c and τ D were tuned for meal challenges (correct CHO estimate, and 50% under- and over-estimates) using a nominal value of τ I = 1.67 h; then τ I was tuned for insulin sensitivity changes. Finally, the resulting PID controller was re-evaluated for the three meal challenges to ensure that postprandial hypoglycemia did not occur, even when the insulin bolus was over-estimated by 50%. In each case, the resulting value of τ I was satisfactory. For each PID controller, K c and τ D were tuned to minimize the following objective function, J = ( ) IAEi + w i + c1 + c 2, (1) i with, IAE = t k e(k) t, (2) w i = exp ( (G min,i ) ), (3) c 1 = exp ( 00 ( 0.01 K c ) ), (4) c 2 = exp ( 00 (1500 τ D ) ), (5) where index i = c, u, o refers to the response for a correct, under-estimated and over-estimated CHO content of the meal; IAE (mg min/dl) is the discrete version of the integral absolute error, w i is the soft constraint to avoid low G values (hypoglycemia); c 1 is the soft constraint to avoid K c values larger than -0.01 mu dl/mg min; c 2 is the soft constraint to avoid τ D values larger than 1500 min; t is duration of the simulation; t is the sampling period (5 min), and G min,i is the minimum value of G f for the i-th run. Note that when the constraints are not active, the objective function is simply the sum of the IAE values for the three cases. IV. CONTROL STRATEGIES In this section a new switching PID control strategy is proposed that consists of meal boluses, a novel PID control algorithm with a time-varying setpoint, and a switching strategy. The proposed strategy (Strategy E, below) will then be compared to four alternative strategies (A D) in Section V. These five control strategies will now be described. A. Bolus only This strategy consists of a constant basal insulin infusion rate plus a meal bolus that is proportional to the estimated CHO for the meal. B. PID control only The PID control algorithm of Section III provides a basis for comparison because many previous studies have considered conventional PID control. C. Bolus plus PID control In this approach, the insulin bolus is introduced at meal time and the PID controller operates continuously. D. Bolus plus PID control with switching criteria The insulin bolus occurs at meal time but the PID controller is not initiated until a switching criterion is satisfied. E. Bolus plus PID control with switching criteria and a timevarying glucose setpoint The novel features of Strategies D and E will now be described in more detail. First, we consider why a switching strategy is desirable. Preliminary simulations for Strategy C indicated that it is detrimental to have the PID controller active during and immediately after an insulin bolus. For this situation, the PID controller senses the increasing glucose level of the post-prandial response and consequently makes the insulin infusion rate greater than its basal value. This additional insulin release leads to hypoglycemia unless the controller is tuned very conservatively. Consequently, the optimal controller settings for Strategy C and the performance index of equations (1) (5), were the minimum allowable values of K c and τ D. Thus, Strategy C was essentially identical to Strategy A, the bolus-only approach, for these conditions. This experience motivated the development of the switching technique that is a key element of Strategies D and E. Improved glucose control for meal challenges and poor CHO estimates can be achieved by starting the PID controller after the meal and bolus occur. However, the specification of the switching time is important. If the PID controller is started too early, hypoglycemia can occur. On the other hand, if the PID controller is switched on too late, the post-prandial glucose peak may be very large and slowly decrease to the setpoint value. Our simulation studies have indicated that an effective switching strategy is obtained if the PID controller is started when one of two criteria is satisfied: (i) G reaches its peak value; (ii) G > 150 mg/dl and dg/dt > 1.5 mg/dl min. The 150 mg/dl threshold was selected because it is the peak value of G for a correct bolus and Strategy A. The rate-ofchange limit of 1.5 mg/dl min was chosen to be greater than the maximum rate of change for this same situation. The rationale for these switching criteria is as follows. When the CHO estimate is either correct or too large, the PID controller switches on when criterion (i) is satisfied. Then the insulin infusion rate starts to decrease because dg/dt < 0. When the CHO estimate is too small, the bolus is also too small and thus when G reaches the threshold of 150 mg/dl, dg/dt is large. Consequently, after the PID controller is switched on, it immediately increases the insulin infusion rate, which is the correct action.

Next, we consider the rationale for using a time-varying glucose setpoint. During the post-prandial period, the blood glucose concentration is expected to increase, and then decrease. Consequently, it is appropriate to have a timevarying setpoint, G sp, that reflects this expected behavior [1], [5]. The following strategy has been devised. When the PID controller is initiated, G sp should be set equal to the current filtered measurement, G f, and then eventually decrease to the desired value of G, mg/dl for this study. However, for the case of a CHO under-estimate, G is still increasing when the PID controller is switched on. Thus, it would be inappropriate to force G sp to decrease right away. Extensive simulations have demonstrated that good glucose control is obtained when the setpoint trajectory is specified as: { mg/dl G sp (k ( if Gf ) (k ) mg/dl ) = (G f (k ) ) exp k τ + otherwise, (6) where k = k k sw, k (min) is the current sampling instant, k sw (min) is the switching instant, and τ (min) is a design parameter. For k < 0, G sp = G f. In order to avoid unexpected hypoglycemia, a lower limit of mg/dl was used. The time-varying setpoint trajectory defined in (6) has the following properties: a. It is affected by the actual value of G f, for every k ; b. It varies from G f (k = 0) to mg/dl; c. As τ 0, G sp (k ) mg/dl; d. As τ, G sp (k ) G f (k ). If G increases, u should increase as well. But when the timevarying setpoint trajectory defined in (6) is used, the error begins to decrease as soon as the controller is switched on. By contrast, for constant G sp, the error would increase. Thus, for the new setpoint trajectory in (6), the derivative term in (??) was modified as, D(k) D(k 1) = τ D ατ D ( ) D(k 1) D(k 2) t + ατ D ( K c Gf (k) 2G f (k 1) + G f (k 2) ). (7) t + ατ D Therefore, if the controller is switched on at the peak in G (switching criterion 1 is satisfied), G starts decreasing and the setpoint trajectory in (6) gradually causes G f to decrease to mg/dl. In the case of a CHO under-estimate, the PID controller is switched on when G f reaches 150 mg/dl (switching criterion 2 is satisfied). But since G is still increasing, the setpoint trajectory will initially increase and then eventually decreases to mg/dl. V. SIMULATION RESULTS The five glucose control strategies of Section IV were evaluated for two situations: (i) Meal challenges and either a correct insulin bolus, a 50% under-bolus, or a 50% over-bolus; (ii) Changes in insulin sensitivity during basal conditions: a 50% increase or a 50% decrease. The incorrect boluses represent situations where the diabetic subject incorrectly estimates the CHO content of the meal. The changes in insulin sensitivity were simulated by making the indicated change in all three of the insulin sensitivities for the Hovorka model [1]. In order to provide a fair comparison of Strategies A E, each PID controller was tuned using the method described in Section III. A. Results for meal challenges The simulation results for a 75 kg patient and a g CHO meal challenge are shown in the left side of Fig. 1 and in Table I. Results for Strategy C are not included in Fig. 1 because they are identical to those for Strategy A, as indicated in Table I and discussed in Section IV. Table I includes several metrics: the maximum and minimum glucose concentrations for each response, G max and G min ; the settling time t s, and the total amount of insulin that was administered, I tot. The settling time was defined to be the time at which the glucose concentration entered and remained with the desired range, 75 to 85 mg/dl. Figure 1 and Table I indicate that the new switching control strategies (D and E) are superior to the standard control strategies (A, B, and C) for these meal challenges due to their smaller IAE values, shorter settling times, and smaller G max value for the under-estimated bolus. Strategy E provides the best control based on these criteria. The I tot values for the five control strategies do not differ significantly. Table I indicates that the G min values for Strategies D and E include small violations of the lower constraint of mg/dl that was used in the controller tuning of Section IV. However, these violations can be eliminated by increasing the weight in the soft constraint for G min in (3) (e.g., use a value of 10,000 instead of ). B. Results for insulin sensitivities changes The simulation results for the two insulin sensitivity changes during basal conditions and no meal are shown in the right side of Fig. 1. As described in Section IV, the tuning procedure for each controller determined the optimal value TABLE I RESULTS FOR MEAL CHALLENGES REJECTION. Control Bolus IAE (10 4 ) G max G min t s Strategy Estimation (mg min/dl) (mg/dl) (mg/dl) (h) correct 1. 150 64 10.2 A under 4.69 202 >18 over 1.68 122 >18 B - 1.97 228 67 6.7 correct 1. 150 64 10.2 C under 4.69 202 >18 over 1.68 122 >18 correct 1.08 150 68 6.2 D under 1.71 192 58 7.1 over 1.10 122 51 12.8 correct 0.99 150 78 3.9 E under 1.61 192 56 8.5 over 0.79 122 56 8.4 Glucose values under mg/dl are reported in boldface.

1 1 (a) Strategy A: bolus only. 0 350 300 250 150 50 (b) Strategy A: bolus only. 1 1 1 1 (c) Strategy B: PID control only. (e) Strategy D: Bolus plus PID control with switching criteria. 1 1 time (h) (g) Strategy E: Bolus plus PID control with switching criteria and time-varying glucose setpoint. (τ = 25 min). (d) Strategy B: PID control only. (f) Strategy D: Bolus plus PID control with switching criteria. time (h) (h) Strategy E: Bolus plus PID control with switching criteria and time-varying glucose setpoint. (τ = 25 min). Fig. 1. Control strategy comparison for meal challenges (left) and insulin sensitivity changes (right). of τ I for insulin sensitivity changes. The simulation results in Fig. 1 are for the optimal value of τ I for that specific change in insulin sensitivity. The results in Fig. 1 demonstrate that Strategies A and C are not able to cope with these sensitivity changes and result in undesirable glucose excursions, which include hypoglycemia. For Strategy B and the 50% decrease in insulin sensitivity, G eventually returns to the desired value of mg/dl but only after a large, slow response. Strategy E provides the best response to the insulin sensitivity changes based on its small IAE values and short settling times. The total insulin utilization is essentially the same for all five control strategies. For strategies D and E, the optimal τ I values were similar for both insulin sensitivity changes. For example, the optimal values of τ I for Strategy E were 3.7 h for the increase and 2.6 h for the decrease.

VI. DISCUSSION OF RESULTS The simulation results demonstrate that an insulin bolus for a meal challenge is required in order to avoid the large glucose peak that occurs when a bolus is not used (Strategy B). However, the bolus-only approach (Strategy A) results in poor glucose control for incorrect boluses and for insulin insensitivity changes. Thus, a combination of insulin boluses for meals and PID control is desirable. But for meal challenges, the PID controller should be switched on at an appropriate time after the bolus is introduced (Strategies D and E); otherwise, it will result in insulin overdosing and hypoglycemia unless it is tuned very conservatively, as was necessary for Strategy B. Furthermore, for the successful application of PID control, it is important to limit the integral control action in order to avoid insulin overdosing. In this study, the integral control action was limited by imposing the constraints in (??). Alternatively, classical anti-resetwindup approaches [6] could be considered. For this simulation study, the proposed Strategy E gave the best performance for both meal challenges and changes in insulin sensitivity. Furthermore, Strategy E is quite robust, that is, insensitive to various types of changes. For example, gain margin calculations [6] for the two insulin sensitivity changes demonstrated that the optimal value of the controller gain K c could be increased by a factor of five before instability occurred in the form of a sustained glucose oscillation. Strategy E also performed well for measurement time delays of 6 to 12 minutes, without having to re-tune the controller. These time delays correspond to the approximate lags associated with the best available subcutaneous glucose sensors. Longer measurements delays could be accommodated by retuning the PID controller. Finally, Strategy E is not unduly sensitive to the numerical value of τ, the tuning parameter for the G sp trajectory. Also, it can be used as a convenient tuning parameter because reducing τ makes the controller more aggressive. The reason that Strategy E outperforms the other four strategies is that the combination of the switching criterion and the time-varying glucose setpoint allows more aggressive controller settings to be used without sacrificing robustness. ACKNOWLEDGMENTS The authors would like to thank the Education Abroad Program (EAP), a program for exchange students and faculty between the University of Padova and the University of California, that made this research possible. The research was performed in collaboration with Francis J. Doyle III, Cesar C. Palerm and Daniel A. Finan (UCSB). Their advise and experience is greatly appreciated. REFERENCES [1] R. Hovorka, V. Canonico, L. J. Chassin, U. Haueter, M. Massi- Benedetti, M. O. Federici, T. R. Pieber, H. C. Schaller, L. Schaupp, T. Vering, and M. E. Wilinska, Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes, Physiol Meas, vol. 25, no. 4, pp. 5 20, 4. [2] R. S. Parker, F. J. Doyle III, and N. A. Peppas, The intravenous route to blood glucose control, IEEE Eng. Med. Biol. Mag., vol. 20, no. 1, pp. 65 73, 1. [3] R. Bellazzi, G. Nucci, and C. Cobelli, The subcutaneous route to insulin dependent diabetes therapy, IEEE Eng. Med. Biol. Mag., vol. 20, no. 1, pp. 54 64, 1. [4] G. M. Steil, A. E. Panteleon, and K. Rebrin, Closed-loop insulin delivery the path to physiological glucose control, Adv Drug Deliv Rev, vol. 56, no. 2, pp. 125 44, 4. [5] B. W. Bequette, A critical assessment of algorithms and challenges in the development of a closed loop artificial pancreas, Diabetes Technol Ther, vol. 7, no. 1, pp. 28 47, 5. [6] D. E. Seborg, T. F. Edgar, and D. A. Mellichamp, Process Dynamics and Control, John Wiley & Sons Ltd., 2nd edn., 4. [7] C. Cobelli, G. Nucci, and S. Del Prato, A physiological simulation model of the glucose insulin system in type I diabetes, Diabetes Nutr Metab, vol. 11, no. 1, p. 78, 1998. [8] R. N. Bergman, The minimal model: yesterday, today, and tomorrow, in R. N. Bergman and J. C. Lovejoy (eds.) The minimal model approach and determinants of glucose tolerance, vol. 7 of Pennington Center Nutrition Series, pp. 3 50, Louisiana State University Press, Baton Rouge, LA, 1997. [9] A. Makroglou, J. Li, and Y. Kuang, Mathematical models and software tools for the glucose-insulin regulatory system and diabetes: an overview, Appl Num Math, vol. 56, no. 3 4, pp. 559 573, 6. [10] M. E. Wilinska, L. J. Chassin, H. C. Schaller, L. Schaupp, T. R. Pieber, and R. Hovorka, Insulin kinetics in type 1 diabetes: Continuous and bolus delivery of rapid acting insulin, IEEE Trans. Biomed. Eng., vol. 52, no. 1, pp. 3 12, 5. VII. CONCLUSIONS A new glucose control strategy has been proposed based on a novel combination of insulin boluses for meals and an improved PID control algorithm. The key features of the control strategy are (i) a switching strategy for determining when to initiate PID control action after a meal, (ii) a novel time-varying trajectory for the glucose setpoint, and (iii) a limit on the integral control action that greatly reduces the possibility of insulin over-dosing. The new control strategy has been compared to four alternatives in a simulation study based on Hovorka s physiological model [1], [10], and was shown to be superior for both insulin sensitivity changes and meal challenges with poor CHO estimates.